Literature DB >> 9646096

[Arteriosclerosis and coronary heart disease--strengths and weaknesses in the classical risk factor concept].

J R Schaefer1, M Herzum.   

Abstract

Several cardiovascular risk factors were identified (high LDL-cholesterol, low HDL-cholesterol, homocystein, Lp(a), and many others). Hypercholesterolemia has been shown to be one of the most important cardiovascular risk factors in man. Interventional studies for primary and secondary prevention demonstrate a beneficial effect of cholesterol lowering therapy. However, numerous CAD-patients suffer a second coronary event despite the appropriate lipid-lowering treatment. Furthermore moderate hypercholesterolemia has only poor predictive power indicating an upcoming myocardial infarction. Therefore we need additional research in CAD prevention and in identifying so far unknown or unconsidered CAD risk factors.

Entities:  

Mesh：

Year:  1998        PMID： 9646096     DOI： 10.1007/bf03044600

Source DB:  PubMed          Journal:  Herz        ISSN： 0340-9937            Impact factor:   1.443


  8 in total

1.  The primary prevention of myocardial infarction.

Authors:  J E Manson; H Tosteson; P M Ridker; S Satterfield; P Hebert; G T O'Connor; J E Buring; C H Hennekens
Journal:  N Engl J Med       Date:  1992-05-21       Impact factor: 91.245

2.  Guide to primary prevention of cardiovascular diseases. A statement for healthcare professionals from the Task Force on Risk Reduction. American Heart Association Science Advisory and Coordinating Committee.

Authors:  S M Grundy; G J Balady; M H Criqui; G Fletcher; P Greenland; L F Hiratzka; N Houston-Miller; P Kris-Etherton; H M Krumholz; J LaRosa; I S Ockene; T A Pearson; J Reed; R Washington; S C Smith
Journal:  Circulation       Date:  1997-05-06       Impact factor: 29.690

Review 3.  George Lyman Duff Memorial Lecture. Lifestyles, major risk factors, proof and public policy.

Authors:  J Stamler
Journal:  Circulation       Date:  1978-07       Impact factor: 29.690

4.  [Risk factor, risk indicator and pathogenesis illustrated by the examples of arteriosclerosis and coronary disease].

Authors:  F H Epstein
Journal:  Med Klin       Date:  1978-03-17

5.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

6.  Incidence rates of fatal and nonfatal myocardial infarction in relation to the lipoprotein profile: first prospective results from the Göttingen Risk, Incidence, and Prevalence Study (GRIPS).

Authors:  P Cremer; H Elster; B Labrot; B Kruse; R Muche; D Seidel
Journal:  Klin Wochenschr       Date:  1988

7.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

Authors: 
Journal:  Lancet       Date:  1994-11-19       Impact factor: 79.321

8.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.

Authors:  J Shepherd; S M Cobbe; I Ford; C G Isles; A R Lorimer; P W MacFarlane; J H McKillop; C J Packard
Journal:  N Engl J Med       Date:  1995-11-16       Impact factor: 91.245
  8 in total
  1 in total

Review 1.  [Prevention of coronary heart disease--"evidence-based medicine" of antilipemic therapy].

Authors:  J R Schaefer; M Herzum; B Maisch
Journal:  Herz       Date:  1999-02       Impact factor: 1.443
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.